

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ONE 32728  
APPLICATION NO.  
Not yet assigned  
APPLICANT  
HOUGHTON ET AL.  
FILING DATE  
Herewith

10/530618  
Sheet 1 of 2

PCT/PTO 27 APR 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/B.P./	AR	J. A. Fagin, "Perspective: Lessons learned from olecular genetic studies of thyroid cancer: Insights into pathogenesis and tumor-specific therapeutic targets," Endocrinology, Vol. 143(6), pp. 2025-2028 (2002)
/B.P./	AS	A. Levitzki, "Tyrosine kinases as targets for cancer therapy," European Journal of Cancer, Vol. 38, pp. S11-S18 (2002)
/B.P./	AT	B. Selle et al., "ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)," Leukemia, Vol. 16(7), pp. 1393-1395 (2002)
EXAMINER	/Benjamin Packard/	
		DATE CONSIDERED 01/10/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

DN4-32721A

APPLICATION NO.

Not yet assigned

APPLICANT

HOUGHTON ET AL.

FILING DATE

Herewith

50 OF 70 638  
Sheet 2 of 2

Rec'd PCT/PTO 07 APR 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/B.P./	BA	5,521,184	5/28/96	Zimmermann			
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	BM	0 564 469	10/0/99	EP			<input type="checkbox"/>	<input type="checkbox"/>
	BN	not provided					<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/B.P./	BR	R. Capdeville et al., "Imatinib: the first 3 years," European Journal of Cancer, Vol. 38, pp. S77-S82 (2002)
/B.P./	BS	Y. Kano et al., "In vitro cytotoxic effects of a tyrosine kinase inhibitor ST1571 in combination with commonly used antileukemic agents," Blood Vol. 97(7), pp. 1999-2007 (2001)
/B.P./	BT	J. Topaly et al., "Synergistic activity of ST1571 with chemotherapeutic drugs and irradiation," Blood, Vol. 96(11), p. 736A (2000)

EXAMINER

/Benjamin Packard/

DATE CONSIDERED

01/10/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.